Literature DB >> 20860651

A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Howard S Kim1, Daniel M Moreira, Matthew R Smith, Joseph C Presti, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Stephen J Freedland.   

Abstract

OBJECTIVES: • To better understand the natural history of weight change with androgen-deprivation therapy (ADT), we investigated the effect of ADT on body weight among men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. • Men undergoing ADT lose lean muscle but gain fat mass, contributing to an overall gain in weight. PATIENTS AND METHODS: • We identified 132 men in SEARCH who received ADT after radical prostatectomy. • 'Weight change' was defined as the difference in weight before starting ADT (6 months before ADT) and the on-ADT weight (between 6 and 18 months after starting ADT). • In a subanalysis, baseline characteristics of weight-gainers and -losers were analysed using univariate and multivariate analysis to test association with weight change.
RESULTS: • In all, 92 men (70%) gained weight, and 40 (30%) either lost or maintained a stable weight. • On average, weight on ADT was 2.2 kg higher than the weight before ADT, with the mean change for weight-gainers and -losers being +4.2 kg and -2.4 kg, respectively. • This compared with no significant weight change in the year before starting ADT (paired t-test, change -0.7 kg, P= 0.19) or in the second year on ADT (paired t-test, change -0.5 kg, P= 0.46) for 84 men in whom these additional weight values were recorded. • There was no significant association between any of the features examined and weight change on univariate and multivariate analysis.
CONCLUSION: • In this longitudinal study, ADT was accompanied by significant weight gain (+2.2 kg). This change occurred primarily in the first year of therapy, with men neither losing nor gaining additional weight thereafter.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20860651      PMCID: PMC3055926          DOI: 10.1111/j.1464-410X.2010.09679.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  21 in total

Review 1.  Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Cancer Metastasis Rev       Date:  2002       Impact factor: 9.264

2.  Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.

Authors:  Hang Lee; Katelyn McGovern; Joel S Finkelstein; Matthew R Smith
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

3.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

4.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

Authors:  E M Messing; J Manola; M Sarosdy; G Wilding; E D Crawford; D Trump
Journal:  N Engl J Med       Date:  1999-12-09       Impact factor: 91.245

5.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  J Natl Cancer Inst       Date:  2009-12-07       Impact factor: 13.506

6.  Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.

Authors:  Shehzad Basaria; Denis C Muller; Michael A Carducci; Josephine Egan; Adrian S Dobs
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

7.  Changes in body composition during androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

Review 8.  Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Authors:  Vahakn B Shahinian; Yong-fang Kuo; Jean L Freeman; Eduardo Orihuela; James S Goodwin
Journal:  Cancer       Date:  2005-04-15       Impact factor: 6.860

9.  Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

10.  Long-term effects of androgen deprivation therapy in prostate cancer patients.

Authors:  Shehzad Basaria; John Lieb; Alice M Tang; Theodore DeWeese; Michael Carducci; Mario Eisenberger; Adrian S Dobs
Journal:  Clin Endocrinol (Oxf)       Date:  2002-06       Impact factor: 3.478

View more
  18 in total

Review 1.  Obesity in cancer survival.

Authors:  Niyati Parekh; Urmila Chandran; Elisa V Bandera
Journal:  Annu Rev Nutr       Date:  2012-04-23       Impact factor: 11.848

Review 2.  Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy.

Authors:  Thomas W Storer; Renee Miciek; Thomas G Travison
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

3.  National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy.

Authors:  Tony Soeyonggo; Jennifer Locke; Maria Elizabeth Del Giudice; Shabbir Alibhai; Neil Eric Fleshner; Padraig Warde
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

4.  Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy.

Authors:  Emma H Allott; Lauren E Howard; Hai-Jun Song; Katharine N Sourbeer; Bridget F Koontz; Joseph K Salama; Stephen J Freedland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-21       Impact factor: 4.254

5.  Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Christopher J Kane; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2018-04-10       Impact factor: 5.588

6.  Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.

Authors:  Alyssa N Troeschel; Terryl J Hartman; Eric J Jacobs; Victoria L Stevens; Ted Gansler; W Dana Flanders; Lauren E McCullough; Ying Wang
Journal:  J Clin Oncol       Date:  2020-04-06       Impact factor: 44.544

7.  First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Authors:  Kagan Griffin; Ilona Csizmadi; Lauren E Howard; Gina-Maria Pomann; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Jennifer Beebe-Dimmer; Stephen J Freedland
Journal:  Cancer Causes Control       Date:  2019-01-30       Impact factor: 2.506

8.  Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Eur Urol       Date:  2013-02-12       Impact factor: 20.096

9.  Trends in Obesity Prevalence in Adults With a History of Cancer: Results From the US National Health Interview Survey, 1997 to 2014.

Authors:  Heather Greenlee; Zaixing Shi; Christine L Sardo Molmenti; Andrew Rundle; Wei Yann Tsai
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

Review 10.  The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease.

Authors:  Abdulmaged M Traish; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.